BioStock: Cyxones expands possibilities for T20K in MS

Recently, Malmö-based company Cyxone, announced the next development steps for its drug candidate T20K for the treatment of multiple sclerosis. A process for large scale production will be developed together with a CMO-partner, while an alternative formulation of the candidate drug is also being considered. BioStock contacted CEO Tara Heitner to learn more about the latest news.

Read the full interview with Tara Heitner at biostock.se:

https://www.biostock.se/en/cyxones-expands-possibilities-for-t20k-in-ms/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/